Osiris Therapeutics (OSIR) Misses Q2 EPS by 20c
Tweet
Share
E-mailGet Alerts OSIR Hot Sheet
Price: $18.99 --0%
Financial Fact:
Research and development: 2.31M
Today's EPS Names:
OTLK, EGRX, MOVE, More
Financial Fact:
Research and development: 2.31M
Today's EPS Names:
OTLK, EGRX, MOVE, More
Join SI Premium – FREE
Osiris Therapeutics (NASDAQ: OSIR) reported Q2 EPS of ($0.04), $0.20 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $13.3 million versus the consensus estimate of $11 million.
For earnings history and earnings-related data on Osiris Therapeutics (OSIR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SanDisk upgraded at JPMorgan after investor day; shares climb
- HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c
- Instil Bio Inc. (TIL) Misses Q2 EPS by 21c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
